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Abstract: Gangliocytomas are rare and benign neuronal cell
tumors, mostly found in the hypothalamic and sellar regions.
Their histogenesis is still the subject of discussions. Herein we
present a unique case of a pituitary gangliocytoma associated
with a prolactinoma and a corticotroph adenoma in a patient
aﬀected by MEN1. The histologic study revealed shared features
between adenomatous and neuronal cells, supporting the etio-
logical hypothesis of a common origin or a phenomenon of
transdiﬀerentiation. Furthermore, gangliocytoma could be a
new tumor related to MEN1. The clinical and histologic ob-
servations are discussed and the literature on the topic is re-
viewed.
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Familial cases of pituitary adenomas (PA) represent upto 5% of all PA, with 2.7% related to multiple endo-
crine neoplasia type 1 (MEN1) and nearly 2.5% are re-
lated to the clinical entity familial-isolated PAs (FIPA).
Mutations in the tumor suppressor gene MEN1 predis-
pose to MEN1, an autosomal dominantly inherited dis-
ease that is characterized by the presence of tumors in at
least 2 endocrine tissues. PA occur in B40% of MEN1
cases with an age of onset between 12 and 83 years (mean
38 y) and a prevalence signiﬁcantly greater in females than
in males. Although PA are larger and more often invasive
in MEN1 patients than in sporadic cases, malignant tumors
are not more frequent.1–5 Considering the histopathology
of PA associated with MEN1 syndrome, prolactinomas are
the most frequent (62%) followed by somatotropinomas
(9%), clinically nonfunctioning (15%), and Cushing disease
(4%). In 2008, Trouillas and colleagues compared 77 sur-
gically resected MEN1 PA with 2509 unselected non-
MEN1 sporadic PA. They concluded that MEN1 tumors
occurred in younger patients and were larger, more in-
vasive, and more aggressive tumors. A higher frequency of
multiple adenomas (4% vs. 0.1%) and hyperplasia (4% vs.
0%) was also found. The frequency of functional PA was
identical in the 2 groups, but the proportion of pluri-
hormonal adenomas was signiﬁcantly higher in the MEN1
group with very unusual associations of hormones: PRL
and adrenocorticotrophic hormone (ACTH) or PRL and
FSH or plurihormonal growth hormone (GH) adenomas.
PA in MEN1 can therefore be seen as having unusual
characteristics as compared with non-MEN1 PA.6 In the
current study, we present the ﬁrst case of a pituitary gan-
gliocytoma associated with a prolactinoma and a cortico-
troph adenoma in a patient with genetically proven MEN1
syndrome.
PATIENT PRESENTATION AND METHODS
In 2003, a 21-year-old man from Cameroon pre-
sented with symptomatic severe hypercalcemia (3.11
mmol/L) due to primary hyperparathyroidism (218
pg/mL) caused by parathyroid hyperplasia. He was
treated surgically with a subtotal parathyroidectomy and
thymectomy. Pathologic examination conﬁrmed hyper-
plasia of the 4 parathyroid glands suggesting a diagnosis
of MEN1 syndrome, which was conﬁrmed by genetic
testing. The patient harbored a MEN1 gene mutation in
exon 6 resulting in a 1015 deletion introducing a pre-
mature stop codon. On investigation, he also had long-
standing symptoms of gastric ulcers and esophagitis since
childhood, Zollinger-Ellison syndrome due to a duodenal
gastrinoma, a pancreatic neuroendocrine tumor, an
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adrenal adenoma, and a double PA with hyper-
prolactinemia. Urinary catecholamines were normal and
there was no hypercortisolism or hyperaldosteronism.
Family history was positive; the patient’s father had
clinical MEN1: a prolactinoma, a pancreatic gastrinoma,
and hyperparathyroidism. The patient had 2 brothers in
good health. Apart from being overweight (96 kg, body
mass index 30.7 kg/m2), the initial physical examination
was normal. In particular there was neither gynecomastia
nor galactorrhea and signs of acromegaly or Cushing
disease were absent. His sexual development had been
unremarkable and he had no erectile dysfunction. He
denied headache or visual disturbance. On laboratory
testing, his serum prolactin (PRL) level was 350 ng/mL
(normal <20 ng/mL), whereas all other hormone levels
were normal. His initial magnetic resonance imagining
(MRI) scan in 2003 showed a macroadenoma of 12mm
on the right side and a microadenoma of 4mm on the left.
Each of these lesions invaded their respective cavernous
sinus (Fig. 1). The patient had bromocriptine and then
cabergoline treatment with doses of the latter pro-
gressively increasing up to 2.5mg weekly. Serum PRL
concentration was reduced but the tumor volumes were
unchanged with persistence of the cavernous sinus in-
vasion. The cabergoline treatment was continued to De-
cember 2013. Between 2003 and 2010, the patient was
asymptomatic with normal PRL and stable pituitary
masses. Otherwise, pituitary hormone serum levels re-
mained normal, particularly ACTH and cortisol at
08:00 AM and after a low-dose dexamethasone suppression
test. The patient stopped his medical follow-up between
2010 and 2013. In 2013, he came back with a signiﬁcant
weight gain (118 vs. 96 kg, body mass index 38 kg/m2),
with faciotruncal fat distribution. He had developed
diabetes mellitus (HBA1c 8.4%). The patient was found
to have Cushing disease (free urinary cortisol at 111 mg/
24 h (normal <60), midnight serum cortisol at 159 ng/
mL, ACTH 22.4 pg/mL at 08:00 AM). The Cushing disease
was conﬁrmed by petrosal sinus sampling. In December
2013, he underwent transphenoidal surgery to remove the
2 tumors. On postsurgical follow-up after 3 months, the
patient’s serum PRL level was normal and the serum
cortisol level had decreased (76 ng/mL at 08:00 AM). He
started to lose weight and blood glucose was well con-
trolled with 2 g of metformin per day. The patient is now
monitored monthly with a urinary-free cortisol level. On
MRI 6 months postoperatively, neither lesion was seen.
On light microscopy, the surgical samples included
some fragments of normal adenohypophysis, a fragment
of neurohypophysis with “corticotroph basophil in-
vasion.” The pars intermedia, immediately in contact with
neurohypophysis, appeared enlarged. A basophilic corti-
cotroph microadenoma with strong immunoreactivity for
ACTH and cytokeratin (CAM5.2) was observed. Other
fragments showed a ﬁbrillary glial/neuropil-like pattern
with 2 intermixed cellular populations. These corre-
sponded to a mature neuronal population resembling
hypothalamic neurons and another comprising endocrine
cells with scant eosinophilic cytoplasm and round nuclei
suggestive of PRL-secreting cells. The neuronal compo-
nent was irregularly distributed, occasionally sparse
against a ﬁbrillary background and also occasionally
forming clusters. The neurons were variable in shape and
size, with binucleation. On immunohistochemistry, the
ﬁbrillary background was positive for synaptophysin and
neuroﬁlament and negative for glial ﬁbrillary acidic pro-
tein; the neurons variably expressed synaptophysin,
chromogranin A, and were negative for neuroﬁlament
and GH-releasing hormone. The endocrine cells in diﬀuse
arrangement were intermingled with the neuronal com-
ponent. The majority of cells were strongly positive for
PRL and a few were positive for b-FSH (about 5%) and
a-SU (<5%). Pit-1 (mammo-somato-thyrotroph tran-
scription factor) immunostaining showed intense nuclear
expression in the PRL-positive cells and also in the nuclei
of all neuronal cells. In contrast, corticotroph cells were
Pit-1 negative. Neurons were immunoreactive for some
anterior pituitary hormones, particularly PRL and rarely
FIGURE 1. MRI at the time of diagnosis (2003). Two lesions are identified on either side of the sella turcica. These lesions are ill-
defined, isointense on coronal T2-weighted images (A) and coronal T1-weighted images (B). Focal spontaneous T1 hyperintensity
(arrow, C) is observed, consistent with hemorrhage. T1 post-gadolinium injection images (C) show 2 well-delimited lesions
(arrows) extending to each cavernous sinus.
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for b-FSH and a-SU (Figs. 2, 3). Overall in both tumor
types no mitoses were found and the Ki-67 index was low
(<1%).
The histologic diagnosis was consistent with a cor-
ticotroph microadenoma and a prolactinoma combined
with a gangliocytoma.
DISCUSSION
We report an exceedingly rare case of a patient with
a double PA associated with a gangliocytoma in the
context of MEN1. Furthermore, the review of the liter-
ature revealed no other cases of gangliocytoma reported
in MEN1 patients. Clinically, the patient presented with
typical MEN1 syndrome with initial symptoms during
childhood/adolescence (Zollinger-Ellison syndrome) and
a diagnosis of pituitary disease at 21 years old. In some
rare cases, a PA is found to coexist with a gangliocytoma.
Worldwide, about 100 cases of PA combined with gan-
gliocytoma have been reported since the ﬁrst description
of this tumor in 1926 by Kiyono and colleagues.7–9
Gangliocytomas are rare and benign neuronal cell tu-
mors, mostly found in the hypothalamic and sellar re-
gions. Histologically these tumors are composed of
mature neuronal cells of variable size, irregular shape
(dystrophic appearance), and one or more 1 nuclei (gan-
glion cells appearance). They are variably immunor-
eactive for synaptophysin, neuron-speciﬁc enolase, and
neuroﬁlament protein (suggesting a neural diﬀer-
entiation).7–9 The neuronal population is accompanied by
a ﬁbrillary nontumoral background comprising glial ele-
ments and neuropil. Ganglion cells may express hypo-
thalamic factors such as GH-releasing hormone or
corticotrophin-releasing hormone, which can stimulate
the growth of anterior pituitary cells and eventually
promote adenoma formation.10–13 Hence, most reported
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FIGURE 2. Histologic examination (40 magnification). A, H&H stain: on the left of the image (*) strongly basophil corticotroph
microadenoma. In the center of the image (1) neurohypophysis with “basophil invasion” and on the right lower part (#) fibrillar
and ganglion cell–rich components of gangliocytoma in collision with nets of endocrine eosinophil cells. B, ACTH im-
munostaining: on the left of the image (*) strongly positive corticotroph microadenoma. In the center of the image (1) neuro-
hypophysis with “basophil invasion” strongly positive for ACTH. On the right lower part (#), absence of ACTH expression in
gangliocytoma/prolactinoma. C, PRL immunostaining: on the right lower part (#) ganglion cells component of gangliocytoma in
collision with nets of endocrine eosinophil cells variably expressing PRL. D, b-FSH immunostaining: on the right lower part (#)
ganglion cells component of gangliocytoma variably expressing b-FSH.
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cases have occurred in the setting of a somatotropinoma
causing acromegaly. Similarly, corticotrophin-releasing
hormone expression in ganglion cells associated with
corticotroph hyperplasia have been described.14 The as-
sociation of a gangliocytoma and a prolactinoma is very
rare (<10 cases in the literature). There are also few cases
of the association of a gangliocytoma and a mixed PA
(GH/PRL). The gangliocytoma may contain some PRL
secretagogues such as PRL-releasing peptide.15–18
The association between gangliocytoma and PAs is
controversial.19 The most popular hypotheses about the
etiology are: (1) hypothalamic-releasing hormone secre-
tion by ganglion neural cells leads to paracrine stim-
ulation and adenomatous cells proliferation as a
secondary phenomenon related to high local concen-
trations of trophic factors20–22; (2) ganglion cells result
from the transdiﬀerenciation of adenomatous cells or are
progenitor cells able to undergo diﬀerentiation into either
endocrine or neuronal cells8,12,13,23,24; or (3) the 2 cell
types occur coincidentally and are unrelated to the de-
velopment of PA in a preexisting neuronal tumor with the
ganglion cell component resulting from the abnormal
migration of neurons from hypothalamus.9 Some studies
observed a lack of correlation between the adenoma cell
type and the corresponding releasing hypothalamic hor-
mones secreted by ganglion cells.25–27 Newer perspectives
suggest that both neuronal and endocrine cells may
originate from the same embryonal pituitary cell rests.
These cellular remnants due to the common ectodermic
embryonal origin of adenohypophysis and the in-
fundibular region may contain intermediate cells showing
features between neuronal and adenohypophyseal ele-
ments (as pituitary progenitor or precursor cells). Some
authors proposed a reinterpretation of this theory af-
ﬁrming the existence of stem cells in adult pituitary that
are capable of multidirectional diﬀerentiation.8,27 In other
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FIGURE 3. Histologic examination (100 magnification). A, H&H stain: fibrillar and ganglion cell–rich components of gan-
gliocytoma in collision with nets of endocrine eosinophil cells: the arrows indicate nets of endocrine eosinophil cells. On the right
side of the image: ganglion cell–rich component in fibrillary background. B, PRL immunostaining: the arrows indicate nets of
endocrine eosinophil cells strongly positive for PRL and the circles show some ganglion cells strongly expressing PRL as cyto-
plasmic granules. C, H&H stain: fibrillar and ganglion cell–rich components of gangliocytoma with numerous binucleated cells in
the circles. D, a-subunit immunostaining: occasional ganglion cells express aSU in cytoplasm. E, b-FSH immunostaining: occa-
sional ganglion cells express b-FSH in cytoplasm. F, Pit-1 immunostaining: numerous nuclei of small size are positive for Pit-1,
corresponding to PRL-positive cells but also large binucleated ganglion cells strongly expressed Pit-1 (circles).
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endocrine organs such as adrenal gland, a possible
pathologic analogue of this, namely pheochromocytoma-
ganglioneuroma, has been well characterized and is also
described in the setting of MEN2. In vitro studies have
reinforced the ability of endocrine neoplastic cells of
pheochromocytoma to transdiﬀerentiate into ganglion
cells when stimulated with NGF.28,29 In our case, we
describe the association of a gangliocytoma and a double
PA in a patient with MEN1. To date, to our knowledge,
this is the ﬁrst case reported in the literature. A high
frequency of multiple adenomas and pituitary hyperplasia
is seen in MEN1,6 but in the literature no evidence of
coexisting gangliocytoma has been reported. The MEN1
gene encodes for the protein Menin, which acts as a tu-
mor suppressor, involved in diﬀerent important cell
functions. Menin interacts with many other proteins, in-
cluding several transcription factors and probably, mod-
ulates cell growth, division, and diﬀerentiation of
endocrine cells. The expression of Pit-1 in both endocrine
(PRL) and neuronal cells may suggest a common ecto-
dermal origin for the two components or a phenomenon
of transdiﬀerentiation. This feature may also explain the
expression of PRL and other anterior pituitary hormones
in the cytoplasm of the ganglion cells. Finally, as recently
suggested elsewhere,8,12,13,23,24,30,31 the term gangliocyto-
ma should be limited to hypothalamic tumors and iso-
lated pituitary gangliocytoma without adenoma. A large
series to verify the expression of anterior pituitary tran-
scription factors in ganglion cell components associated
with PAs is required to validate the hypothesis that the 2
components have the same ectodermal origin.
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